Intraputaminal Delivery of Adeno‐Associated Virus Serotype 2–Glial Cell Line–Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease

Bilateral intraputaminal AAV2-GDNF gene therapy was well tolerated and associated with numerical stability (mild cohort) and improvement (moderate cohort) in clinical assessments at 18 months posttreatment. © 2025 AskBio Inc and The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.